Cargando…

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia

Acquired haemophilia A is a serious and potentially fatal bleeding disorder. Diagnosis is difficult and maybe delayed due to its rarity. The high mortality rate and the complex nature of treatment necessitate patient management at a haemophilia centre, where the required expertise and resources are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaher, Galila, Adam, Soheir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2012
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335817/ https://www.ncbi.nlm.nih.gov/pubmed/22536478 http://dx.doi.org/10.4084/MJHID.2012.021

Ejemplares similares

Efficacy of Corticosteroids Alone in the Eradication of Factor VIII Inhibitor in an Old Female with Idiopathic Acquired Haemophilia A: Description of a Case
por: Girelli, Francesco, et al.
Publicado: (2012)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Association of Genetic Variant FVIII Gene and Factor VIII: A Pilot Study Among Hemophilia A Female Relatives in Saudi Arabia
por: Almohammadi, Abdullah T, et al.
Publicado: (2023)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
por: Iioka, F, et al.
Publicado: (2014)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Autologous cell therapy – A new concept to eradicate inhibitors in haemophilia
por: Xie, Hanjing, et al.
Publicado: (2022)

Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)

Long-term efficacy and safety of a pasteurized, plasma-derived factor VIII concentrate (Beriate(®) P) in patients with haemophilia A
por: Klamroth, Robert, et al.
Publicado: (2014)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult‐to‐treat patients
por: Ljung, Rolf, et al.
Publicado: (2018)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding
por: Pacheco Cano, Carlos I., et al.
Publicado: (2018)

Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur
por: Miatech, Jennifer L, et al.
Publicado: (2021)

Acquired factor VIII inhibitor caused by solid tumor malignancy
por: de Bear, Olivia, et al.
Publicado: (2023)

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
por: Romanová, Gabriela, et al.
Publicado: (2023)

Utilization of Emicizumab in Acquired Factor VIII Deficiency
por: Hess, Kevin J., et al.
Publicado: (2020)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Acquired Haemophilia A: An Intriguing Disease
por: Mazzucconi, Maria Gabriella, et al.
Publicado: (2020)

Acquired Haemophilia Associated with Urticarial Vasculitis
por: Attout, Hassene
Publicado: (2020)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Acquired factor VIII inhibitor syndrome: A rare cause of hematuria
por: Kannan, Muthuvel Seral, et al.
Publicado: (2015)

PROTECT VIII kids extension study: Long‐term safety and efficacy of BAY 94‐9027 (damoctocog alfa pegol) in children with severe haemophilia A
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study
por: Reding, Mark T., et al.
Publicado: (2021)

Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
por: Kiialainen, Anna, et al.
Publicado: (2022)

AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study
por: Shima, Midori, et al.
Publicado: (2022)

Acquired Haemophilia A in the Elderly: Case Reports
por: Tufano, Antonella, et al.
Publicado: (2010)

Doxycycline: Acquired haemophilia A: case report
Publicado: (2021)

Tozinameran: Acquired Haemophilia A: case report
Publicado: (2021)

Report of Two Cases of Acquired Idiopathic Haemophilia
por: Silva, Clara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_goo8kqdomqosqsur79gkoo9drc